<DOC>
	<DOCNO>NCT01500928</DOCNO>
	<brief_summary>The Purpose study evaluate performance SOLO ( version 2.0 ) micropump insulin delivery system , Type 1 diabetic patient use insulin pump treatment .</brief_summary>
	<brief_title>Performance Study SOLO 2.0 Insulin Pump</brief_title>
	<detailed_description>This multi center , one arm , open label prospective study ass safety quality SOLO 2.0 MicroPump Insulin Delivery System , follow change do SOLO previous version validate 54 subject . SOLO 2.0 intend use core technology previous SOLO addition safety measure , GUI change design change manufacturability . The study include 30 day treatment period Solo MicroPump special care require maintain glycemic control optional extension period three month Israel six month Austria . The study include 3 schedule treatment one follow phone call one week termination study . In case participate extension period , additional visit consist month . The study include 3 schedule treatment visit one schedule telephone call Visit 1 include eligibility , baseline evaluation training handle SOLO System . If additional practice require patient enrol . Visit 2 commence Solo pump fill insulin . If additional practice require subject send home additional training period day practice use saline return visit 2 . Treatment visit take place 3 , 10 30 day enrolment . Additional visit take place 60 , 90 , 120 150 day depend extension period . Medical assessment include DTSQ information , Subject Diary , urine &amp; blood sampling , physical examination , SOLO Performance Questionnaire , R &amp; D Questionnaire Complaint Report Forms.Subjects ask record blood glucose measurement , daily activity carbohydrate consumption visit . Seven day termination study treatment telephone contact study subject take place purpose adverse event report completion DTSQ questionnaire .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age range : 16 65 year ( Graz ) 18 65 year ( Israel ) Diabetic insulin pump user diagnosis duration 6 month . Subjects use Humalog® , NovoRapid®/NovoLog Apidra® 100U/ml Measures glucose least four time per day . No one severe hypoglycemic ketoacidosis episode within one year Willing sign inform consent . Cooperative , willing attend study visit A1c &gt; = 10.0 % Two documented event severe hypoglycemia within previous 12 month Diabetes relate hospitalization past 12 month Current significant diabetesrelated complication Pregnant , lactate plan become pregnant course study Substance alcohol abuse Uncontrolled hypertension Known dermal hypersensitivity medical adhesive Recurrent episode skin infection dermatological allergy Serious unstable medical psychological condition Current participation clinical study . Working competitor company</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Insulin Pump</keyword>
	<keyword>Glycemic Control</keyword>
	<keyword>Type 1 Diabetes</keyword>
</DOC>